Lucid Diligence Brief: AlzeCure Pharma Collaboration and Out-Licensing Agreement with Eli Lilly
Lucid Diligence Brief: AlzeCure Pharma Collaboration and Out-Licensing…
Nurix Roche Bexobrutideg Deal | Lucid Diligence Brief
Roche’s collaboration with Nurix turns bexobrutideg into a multi-indication BTK…
Ascidian and Lilly $1.9B Deal for Kidney RNA Editing | Lucid Diligence Brief
Ascidian and Lilly $1.9B collaboration tests whether RNA exon editing can move…
Servier Edgewise Sevasemten Deal | Lucid Diligence Brief
Servier’s Edgewise acquisition puts sevasemten’s Becker muscular dystrophy data…
Lucid Diligence Brief: Olema OP-3136 and Bayer Darolutamide Deal
Lucid Diligence Brief: Olema expands OP-3136 into metastatic…
Lucid Diligence Brief: SELLAS REGAL AML Phase 3 Nears Final Analysis
Lucid Diligence Brief: SELLAS approaches REGAL AML final analysis for…
Lucid Diligence Brief: Insilico and Human Longevity collaboration
Lucid Diligence Brief: Insilico Medicine and Human Longevity collaborate on AI…
Lucid Diligence Brief: NeuroXT and BIDMC Expand Alzheimer’s AI Imaging Collaboration
Lucid Diligence Brief: NeuroXT and BIDMC expand their Alzheimer’s AI imaging…
Lucid Diligence Brief: BMS Deploys Anthropic Claude Enterprise
Lucid Diligence Brief: BMS Deploys Anthropic Claude Enterprise Across R&D,…
Lucid Diligence Brief: Catalent and Elpida Therapeutics announced a strategic partnership for late-phase AAV manufacturing
Lucid Diligence Brief: Catalent and Elpida Therapeutics announced a strategic…
Lucid Diligence Brief: Roche to acquire PathAI
Lucid Diligence Brief: Roche acquires PathAI for USD 1.05B to advance AI…
Lucid Diligence Brief: Bayer to Acquire Perfuse Therapeutics for Up to $2.45B
Lucid Diligence Brief: Bayer to Acquire Perfuse Therapeutics for Up to $2.45B…